Published in the New England Journal of Medicine in October, the POPular TAVI trial randomized 665 patients under-going transcatheter aortic valve replacement to receive either aspirin alone or aspirin plus clopidogrel post-procedure. Bleeding occurred in 15.1% of the aspirin only group and 26.6% of the dual-antiplatelet group. There was no statistically significant difference in death from any cause, stroke, or myocardial infarction between groups. The authors concluded that aspirin alone and not dual-antiplatelet therapy was appropriate for patients without an indication for anticoagulation under-going trans-catheter aortic valve replacement. These findings are consistent with the ARTE trial published in 2017 in the context of balloon-expandable valves.